Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
P/B ratio for Rani Therapeutics Holdings, Inc. (RANI)
P/B ratio as of 2023: 6.58
According to Rani Therapeutics Holdings, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 6.58. At the end of 2022 the company had a P/B ratio of 3.81.
P/B ratio history for Rani Therapeutics Holdings, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 6.58 |
| 2022 | 3.81 |
| 2021 | 6.80 |
| 2020 | -1.92 |
| 2019 | -2.25 |